ACM
CYTK icon

AlphaCrest Capital Management’s Cytokinetics CYTK Stock Holding History

AlphaCrest Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,763
Closed -$279K – 298
2022
Q3 		$279K Buy
+5,763
New +$277K 0.02% 1164
2021
Q3 		– Sell
-19,909
Closed -$394K – 1263
2021
Q2 		$394K Buy
+19,909
New +$467K 0.02% 1031

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

AlphaCrest Capital Management's CYTK Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Cytokinetics (CYTK) in Q4 2022, closing a stake of 5,763 shares — an estimated $279K sold.

AlphaCrest Capital Management first reported a position in CYTK in Q2 2021 and held it in 2 quarters. The position peaked at $394K in Q2 2021. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Cytokinetics position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 5,763 Cytokinetics shares in Q4 2022, an estimated $279K.
  • AlphaCrest Capital Management first reported a position in Cytokinetics in Q2 2021 and held it in 2 quarters.
  • AlphaCrest Capital Management's Cytokinetics position peaked at $394K in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.